NCT06784193 - Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

May 30, 2027

Study Completion Date

August 30, 2027

Conditions

Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Breast CancerFulvestrantPalazestrant

Interventions

DRUG

OP-3136

Selective inhibitor of HAT enzymes KAT6A and KAT6B

DRUG

Fulvestrant

Selective estrogen receptor degrader (SERD)

DRUG

Palazestrant

Complete estrogen receptor antagonist (CERAN)

Trial Locations (8)

5000

RECRUITING

Cancer Research South Australia, Adelaide

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

SCRI Oncology Partners, Nashville

49546

RECRUITING

START - Midwest, Grand Rapids

70112

RECRUITING

University Medical Center - New Orleans, New Orleans

78229

RECRUITING

START - San Antonio, San Antonio

84119

RECRUITING

START - Mountain Region, West Valley City

02215

RECRUITING

Dana-Farber Cancer Institute, Boston